Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Alkylating Agents
  • 1.3.3 Cytotoxic Antibiotics
  • 1.3.4 Topoisomerase Inhibitors
  • 1.3.5 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Myelodysplastic Syndrome Market Share by Application (2019-2025)
  • 1.4.2 Hospital
  • 1.4.3 Clinic
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Myelodysplastic Syndrome Market Size
  • 2.1.1 Global Myelodysplastic Syndrome Revenue 2014-2025
  • 2.1.2 Global Myelodysplastic Syndrome Sales 2014-2025
• 2.2 Myelodysplastic Syndrome Growth Rate by Regions
  • 2.2.1 Global Myelodysplastic Syndrome Sales by Regions 2014-2019
  • 2.2.2 Global Myelodysplastic Syndrome Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Myelodysplastic Syndrome Sales by Manufacturers
  • 3.1.1 Myelodysplastic Syndrome Sales by Manufacturers 2014-2019
  • 3.1.2 Myelodysplastic Syndrome Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Myelodysplastic Syndrome Revenue by Manufacturers (2014-2019)
  • 3.2.2 Myelodysplastic Syndrome Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)
• 3.3 Myelodysplastic Syndrome Price by Manufacturers
• 3.4 Key Manufacturers Myelodysplastic Syndrome Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Myelodysplastic Syndrome Market
• 3.6 Key Manufacturers Myelodysplastic Syndrome Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Alkylating Agents Sales and Revenue (2014-2019)
  • 4.1.2 Cytotoxic Antibiotics Sales and Revenue (2014-2019)
  • 4.1.3 Topoisomerase Inhibitors Sales and Revenue (2014-2019)
  • 4.1.4 Others Sales and Revenue (2014-2019)
• 4.2 Global Myelodysplastic Syndrome Sales Market Share by Type
• 4.3 Global Myelodysplastic Syndrome Revenue Market Share by Type
• 4.4 Myelodysplastic Syndrome Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Myelodysplastic Syndrome Sales by Application

6 United States

• 6.1 United States Myelodysplastic Syndrome Breakdown Data by Company
• 6.2 United States Myelodysplastic Syndrome Breakdown Data by Type
• 6.3 United States Myelodysplastic Syndrome Breakdown Data by Application

7 European Union

• 7.1 European Union Myelodysplastic Syndrome Breakdown Data by Company
• 7.2 European Union Myelodysplastic Syndrome Breakdown Data by Type
• 7.3 European Union Myelodysplastic Syndrome Breakdown Data by Application

8 China

• 8.1 China Myelodysplastic Syndrome Breakdown Data by Company
• 8.2 China Myelodysplastic Syndrome Breakdown Data by Type
• 8.3 China Myelodysplastic Syndrome Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Myelodysplastic Syndrome Breakdown Data by Company
• 9.2 Rest of World Myelodysplastic Syndrome Breakdown Data by Type
• 9.3 Rest of World Myelodysplastic Syndrome Breakdown Data by Application
• 9.4 Rest of World Myelodysplastic Syndrome Breakdown Data by Countries
  • 9.4.1 Rest of World Myelodysplastic Syndrome Sales by Countries
  • 9.4.2 Rest of World Myelodysplastic Syndrome Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Celgene
  • 10.1.1 Celgene Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.1.4 Myelodysplastic Syndrome Product Introduction
  • 10.1.5 Celgene Recent Development
• 10.2 Novartis
  • 10.2.1 Novartis Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.2.4 Myelodysplastic Syndrome Product Introduction
  • 10.2.5 Novartis Recent Development
• 10.3 Otsuka
  • 10.3.1 Otsuka Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.3.4 Myelodysplastic Syndrome Product Introduction
  • 10.3.5 Otsuka Recent Development
• 10.4 Actinium Pharmaceuticals
  • 10.4.1 Actinium Pharmaceuticals Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.4.4 Myelodysplastic Syndrome Product Introduction
  • 10.4.5 Actinium Pharmaceuticals Recent Development
• 10.5 Acceleron Pharma
  • 10.5.1 Acceleron Pharma Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.5.4 Myelodysplastic Syndrome Product Introduction
  • 10.5.5 Acceleron Pharma Recent Development
• 10.6 Bellicum Pharmaceuticals
  • 10.6.1 Bellicum Pharmaceuticals Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.6.4 Myelodysplastic Syndrome Product Introduction
  • 10.6.5 Bellicum Pharmaceuticals Recent Development
• 10.7 Cornerstone Pharmaceuticals
  • 10.7.1 Cornerstone Pharmaceuticals Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.7.4 Myelodysplastic Syndrome Product Introduction
  • 10.7.5 Cornerstone Pharmaceuticals Recent Development
• 10.8 CTI BioPharma
  • 10.8.1 CTI BioPharma Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.8.4 Myelodysplastic Syndrome Product Introduction
  • 10.8.5 CTI BioPharma Recent Development
• 10.9 Onconova Therapeutics
  • 10.9.1 Onconova Therapeutics Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.9.4 Myelodysplastic Syndrome Product Introduction
  • 10.9.5 Onconova Therapeutics Recent Development
• 10.10 Strategia Therapeutics
  • 10.10.1 Strategia Therapeutics Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome
  • 10.10.4 Myelodysplastic Syndrome Product Introduction
  • 10.10.5 Strategia Therapeutics Recent Development
• 10.11 KaloBios Pharmaceuticals
• 10.12 Kiadis Pharma
• 10.13 Mirati Therapeutics
• 10.14 Astex
• 10.15 Celator Pharmaceuticals
• 10.16 Eli-lilly
• 10.17 Sunesis Pharmaceuticals
• 10.18 Targazyme
• 10.19 Gamida Cell
• 10.20 GlaxoSmithKline
• 10.21 Sumitomo Dainippon Pharma
• 10.22 TetraLogic Pharmaceuticals

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Myelodysplastic Syndrome Sales Channels
  • 11.2.2 Myelodysplastic Syndrome Distributors
• 11.3 Myelodysplastic Syndrome Customers

12 Market Forecast

• 12.1 Global Myelodysplastic Syndrome Sales and Revenue Forecast 2019-2025
• 12.2 Global Myelodysplastic Syndrome Sales Forecast by Type
• 12.3 Global Myelodysplastic Syndrome Sales Forecast by Application
• 12.4 Myelodysplastic Syndrome Forecast by Regions
  • 12.4.1 Global Myelodysplastic Syndrome Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Myelodysplastic Syndrome Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.[2] Early on there are typically no symptoms.Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections.[2] Some types may develop into acute myeloid leukemia.
The presence of diagnostic tools is the key driver for the growth of this market. Diagnosis techniques like blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS. Consequently, these diagnostic tools are expected to have a positive impact on the usage of drugs for people suffering from MDS.
In 2019, the market size of Myelodysplastic Syndrome is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Myelodysplastic Syndrome.

This report studies the global market size of Myelodysplastic Syndrome, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Myelodysplastic Syndrome sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Strategia Therapeutics
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli-lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
GlaxoSmithKline
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals

Market Segment by Product Type
Alkylating Agents
Cytotoxic Antibiotics
Topoisomerase Inhibitors
Others

Market Segment by Application
Hospital
Clinic

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Myelodysplastic Syndrome status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Myelodysplastic Syndrome manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Myelodysplastic Syndrome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025